Our findings, which demonstrated the benefits associated with GLP-1 RAs in reductions in incident HF, decompensated HF, and progression to ESKD, align with the outcome pattern of GLP-1 RAs identified in both the FLOW and SUMMIT trials. Here, GLP1R is linked to hydrops fetalis.